70% Repatha Cut? Amgen Counters With Own Study To Justify Price - Xconomy

Medscape70% Repatha Cut? Amgen Counters With Own Study To Justify PriceXconomyWriting in the Journal of the American Medical Association, researchers at the University of California, San Francisco argued this week that the price of the cholesterol-fighting drug evolocumab (Repatha) should come down 70 percent, to $4,215 a year ...PCSK9 Inhibitors Still Burdened by Poor Cost-effectiveness, Despite FOURIER: New AnalysesMedscapeDueling data: Amgen fires back over cost effectiveness for its cholesterol drugSTATNo need for 60%-plus discounts on Repatha, Amgen says, rolling out real-world data as backupFiercePharmaStreetInsider.comall 10 news articles »